Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Daily Life: Managing Digestion, Pain, and Nutrition

At a Glance

Daily management of exocrine pancreatic cancer may include pancreatic enzymes with meals and snacks, nutrition support, blood sugar monitoring, multimodal pain treatment, and procedures to relieve bile duct or stomach outlet blockages.

Managing pancreatic cancer on a daily basis involves more than just treating the tumor; it requires a proactive approach to nutrition and pain control. Because the pancreas is the body’s primary engine for digestion and blood sugar regulation, a diagnosis often leads to Exocrine Pancreatic Insufficiency (EPI) and pancreatogenic diabetes [1][2]. Addressing these symptoms early is essential for maintaining the strength needed for treatment.

Managing Digestion: EPI and PERT

When a tumor blocks the pancreatic duct or when part of the pancreas is removed, the organ can no longer produce enough enzymes to break down fat and protein. This is Exocrine Pancreatic Insufficiency (EPI), and it affects about 72% of people with advanced pancreatic cancer [3].

Untreated EPI leads to malnutrition, rapid weight loss, and a significant decrease in quality of life [3][4]. To manage this, doctors prescribe Pancreatic Enzyme Replacement Therapy (PERT).

  • How to Take PERT: Enzymes must be taken with every meal and snack [5]. For the best results, one approach is to “sandwich” the capsules by taking some at the start and the rest halfway through the meal to ensure they mix thoroughly with your food [1][6].
  • Dosing: Doses are measured in lipase units and must be prescribed by your care team. A common starting dose is 25,000 to 40,000 units of lipase per meal and half that for snacks [5]. Your team may titrate (increase) this dose if you continue to have oily stools or weight loss [6]. Do not escalate your dose independently. If symptoms persist despite high doses, your doctor and dietitian will check your adherence, timing, and storage of the medication before adjusting the dose or adding an acid-suppressing medication (like a PPI) to help the enzymes work better in your small intestine [5][7].
  • Signs it’s Working: You should see a decrease in bloating, gas, and steatorrhea (oily, foul-smelling stools) [1].

Blood Sugar: Pancreatogenic (Type 3c) Diabetes

When the pancreas is damaged by a tumor or surgery, it can stop producing not just digestive enzymes, but also insulin and glucagon. This results in Type 3c diabetes [2].

Unlike more common forms of diabetes, Type 3c can be “brittle,” meaning your blood sugar may swing quickly from very high to very low [8]. This happens because you may be missing glucagon, the hormone that normally prevents your blood sugar from dropping too far [9]. Using a Continuous Glucose Monitor (CGM) can be particularly helpful for catching these dangerous drops, especially at night [8].

Hypoglycemia Action Plan: Always know what to do if your blood sugar drops. If you feel shaky, sweaty, or suddenly confused and are awake and able to swallow, drink juice or take glucose tablets. If you become severely confused, have a seizure, or cannot swallow, no one should give you food or drink; your caregivers should administer prescribed emergency glucagon and call 911 [8][9]. Working closely with an endocrinologist is strongly recommended.

Multimodal Pain Management

Pancreatic cancer pain can be intense because the pancreas is surrounded by a dense network of nerves. A “multimodal” approach uses different types of treatments together to achieve relief while minimizing side effects like the “fog” or constipation caused by opioids [10].

  • Medications: This typically includes a combination of long-acting and fast-acting opioids, plus “adjuvants” like gabapentin for nerve pain or steroids to reduce inflammation [11][12].
  • Celiac Plexus Neurolysis (CPN): This is a specialized procedure, often performed during an EUS, where a doctor injects alcohol into the nerves (the celiac plexus) near the pancreas to “short-circuit” the pain signals [13]. While it can provide relief, the response is variable and often temporary, and it does not always eliminate the need for opioids [14][15]. Important risks include diarrhea, a temporary drop in blood pressure, bleeding, infection, and rare nerve injury.

Relieving Obstructions

If the tumor physically blocks the bile duct or the exit of the stomach, your quality of life can drop quickly. Specialized “plumbing” fixes can offer rapid relief:

  • Biliary Stents: If the bile duct is blocked (causing jaundice), an ERCP procedure is used to place a small metal or plastic tube (stent) to keep the duct open [16][17].
  • Gastric Outlet Obstruction: If you cannot keep food down because the tumor is blocking the duodenum (the start of the small intestine), a surgeon or gastroenterologist may place an enteral stent or perform an EUS-guided gastroenterostomy to create a bypass for food to flow through [18][19].

These interventions are designed to keep you comfortable and nourished so that you can focus on your primary cancer treatments.

Common questions in this guide

What is exocrine pancreatic insufficiency in pancreatic cancer?
Exocrine pancreatic insufficiency, or EPI, happens when a tumor or pancreatic surgery leaves the pancreas unable to release enough digestive enzymes. It can cause bloating, gas, oily foul-smelling stools, malnutrition, and weight loss. Pancreatic enzyme replacement therapy is used to help digest food.
How should I take pancreatic enzymes with meals?
Take pancreatic enzyme replacement therapy with every meal and snack, not only once a day. Your care team may recommend taking part of the dose at the start and the rest halfway through the meal so the enzymes mix with food. Do not increase the dose on your own; persistent symptoms should be reviewed by your care team.
What should I do if oily stools continue while taking pancreatic enzymes?
Oily stools, bloating, gas, or ongoing weight loss can mean exocrine pancreatic insufficiency is not fully controlled. Ask your doctor or dietitian to review the dose, timing, adherence, and storage before changing treatment; they may adjust the dose or add an acid-suppressing medicine. Do not change the dose independently.
Why can pancreatic cancer cause dangerous low blood sugar?
Damage to the pancreas can affect both insulin and glucagon, causing type 3c diabetes with quick swings from high to low blood sugar. A continuous glucose monitor may help detect drops, including overnight. If someone is severely confused, has a seizure, or cannot swallow, do not give food or drink; use prescribed emergency glucagon and call 911.
What pain treatments are available for pancreatic cancer?
Pain care may combine long-acting and fast-acting opioids with medicines such as gabapentin or steroids. A celiac plexus neurolysis procedure, which interrupts pain signals near the pancreas, may reduce pain for some people, but relief varies, may be temporary, and does not always remove the need for opioids. Discuss risks such as diarrhea, low blood pressure, bleeding, infection, and rare nerve injury with your specialist.
How are blockages caused by pancreatic cancer treated?
A blocked bile duct that causes jaundice may be opened with a biliary stent placed during ERCP. If a tumor blocks the stomach outlet or duodenum, an enteral stent or an EUS-guided gastroenterostomy may create a route for food to pass. These procedures are intended to improve comfort and nutrition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms and weight, what is my starting dose of pancreatic enzymes (PERT), and how should I adjust it if my stools remain oily?
  2. 2.Do I need a fecal elastase-1 test to confirm my pancreatic insufficiency, or should we start enzymes based on my symptoms alone?
  3. 3.I have 'pancreatogenic' (Type 3c) diabetes; how does this differ from typical Type 2 diabetes in terms of my risk for low blood sugar?
  4. 4.Is a celiac plexus block an option for my pain, and what are the specific risks and expected duration of relief?
  5. 5.If my bile duct stent becomes blocked, what are the early warning signs I should look for before it becomes an emergency?
  6. 6.Can you refer me to an oncology dietitian who specializes in pancreatic cancer to help me manage my weight and enzyme dosing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.

    Whitcomb DC, Buchner AM, Forsmark CE

    Gastroenterology 2023; (165(5)):1292-1301 doi:10.1053/j.gastro.2023.07.007.

    PMID: 37737818
  2. 2

    Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).

    Hart PA, Andersen DK, Bellin MD, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2026; (26(4)):581-586 doi:10.1016/j.pan.2026.04.001.

    PMID: 41956866
  3. 3

    Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis.

    Iglesia D, Avci B, Kiriukova M, et al.

    United European gastroenterology journal 2020; (8(9)):1115-1125 doi:10.1177/2050640620938987.

    PMID: 32631175
  4. 4

    Defining the rate of nutritional and metabolic derangements after pancreatic resection.

    Percy KL, Ooi YX, Nahm CB, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2022; (22(7)):1028-1034 doi:10.1016/j.pan.2022.07.014.

    PMID: 35948507
  5. 5

    Diagnosis and management of pancreatic exocrine insufficiency.

    Nikfarjam M, Wilson JS, Smith RC,

    The Medical journal of Australia 2017; (207(4)):161-165 doi:10.5694/mja16.00851.

    PMID: 28814218
  6. 6

    Pancreatic Enzyme Replacement Therapy: A Concise Review.

    Brennan GT, Saif MW

    JOP : Journal of the pancreas 2019; (20(5)):121-125.

    PMID: 31736680
  7. 7

    Exocrine Pancreatic Insufficiency Dosing Guidelines for Pancreatic Enzyme Replacement Therapy Vary Widely Across Disease Types.

    Lewis DM, Rieke JG, Almusaylim K, et al.

    Digestive diseases and sciences 2024; (69(2)):615-633 doi:10.1007/s10620-023-08184-w.

    PMID: 38117426
  8. 8

    Continuous Glucose Monitoring for the Detection of Hypoglycemia in Patients With Diabetes of the Exocrine Pancreas.

    Shivaprasad C, Gautham K, Shah K, et al.

    Journal of diabetes science and technology 2021; (15(6)):1313-1319 doi:10.1177/1932296820974748.

    PMID: 33322930
  9. 9

    Negotiating the complexities of exocrine and endocrine dysfunction in chronic pancreatitis.

    Duggan SN

    The Proceedings of the Nutrition Society 2017; (76(4)):484-494 doi:10.1017/S0029665117001045.

    PMID: 28735575
  10. 10

    Pain management in pancreatic cancer: time to change our strategy!

    Blero D, Hendlisz A

    Current opinion in oncology 2026; (38(4)):359-363 doi:10.1097/CCO.0000000000001251.

    PMID: 42240215
  11. 11

    Pathophysiology, assessment, and treatment of pain in patients with pancreatic ductal adenocarcinoma.

    Faghih M, Damm M, Gutzler C, et al.

    Journal of gastroenterology 2026; doi:10.1007/s00535-026-02423-3.

    PMID: 42068358
  12. 12

    Navigated magnetic resonance imaging-guided celiac plexus neurolysis using an open magnetic resonance system for pancreatic cancer patients with upper abdominal pain.

    Jin G, Qiu X, Ding M, et al.

    Journal of cancer research and therapeutics 2019; (15(4)):825-830 doi:10.4103/jcrt.JCRT_38_19.

    PMID: 31436238
  13. 13

    Systematic review and meta-analysis of celiac plexus neurolysis for abdominal pain associated with unresectable pancreatic cancer.

    Okita M, Otani K, Gibo N, Matsui S

    Pain practice : the official journal of World Institute of Pain 2022; (22(7)):652-661 doi:10.1111/papr.13143.

    PMID: 35748531
  14. 14

    Practice guidelines for endoscopic ultrasound-guided celiac plexus neurolysis.

    Wyse JM, Battat R, Sun S, et al.

    Endoscopic ultrasound 2017; (6(6)):369-375 doi:10.4103/eus.eus_97_17.

    PMID: 29251270
  15. 15

    Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) technique and analgesic efficacy in patients with pancreatic cancer: A systematic review and meta-analysis.

    Koulouris AI, Alexandre L, Hart AR, Clark A

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(2)):434-442 doi:10.1016/j.pan.2020.12.016.

    PMID: 33461931
  16. 16

    Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort.

    Inamdar S, Slattery E, Bhalla R, et al.

    JAMA oncology 2016; (2(1)):112-7 doi:10.1001/jamaoncol.2015.3670.

    PMID: 26513013
  17. 17

    Survival analysis among unresectable pancreatic adenocarcinoma patients undergoing endoscopic or percutaneous interventions.

    Tavakkoli A, Elmunzer BJ, Waljee AK, et al.

    Gastrointestinal endoscopy 2021; (93(1)):154-162.e5 doi:10.1016/j.gie.2020.05.061.

    PMID: 32531402
  18. 18

    EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: a prospective cohort study with matched comparison with enteral stenting.

    Vanella G, Dell'Anna G, Capurso G, et al.

    Gastrointestinal endoscopy 2023; (98(3)):337-347.e5 doi:10.1016/j.gie.2023.04.2072.

    PMID: 37094692
  19. 19

    Clinical outcome of a highly flexible duodenal stent for gastric outlet obstruction: A multicenter prospective study.

    Miwa H, Sugimori K, Kaneko T, et al.

    JGH open : an open access journal of gastroenterology and hepatology 2020; (4(4)):729-735 doi:10.1002/jgh3.12326.

    PMID: 32782963

This page is for informational purposes only and does not replace medical advice. Your oncology, gastroenterology, endocrinology, pain, and nutrition teams should tailor enzyme therapy, diabetes care, pain treatment, and procedures to your situation.

Get notified when new evidence is published on exocrine pancreatic carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.